Low-dose methotrexate enhances cycling of highly anaplastic cancer cells

References

• Marzi I, Cipolleschi MG, D’Amico M, Stivarou T, Rovida E, Vinci MC, Pandolfi S, Dello Sbarba P, Stecca B, Olivotto M. The involvement of a Nanog, Klf4 and c-Myc transcriptional circuitry in the intertwining between neoplastic progression and reprogramming. Cell Cycle 2013; 12:353-64; PMID:23287475; http://dx.doi.org/10.4161/cc.23200
   PubMed Web of Science ®Google Scholar
• Cipolleschi MG, Marzi I, Santini R, Fredducci D, Vinci MC, D'Amico M, Rovida E, Stivarou T, Torre E, Dello Sbarba P, Stecca B, Olivotto M. Hypoxia-resistant profile implies vulnerability of cancer stem cells to physiological agents, which suggests new therapeutic targets. Cell Cycle 2014; 13:268-78; PMID:24200964; http://dx.doi.org/10.4161/cc.27031
   PubMed Web of Science ®Google Scholar
• Bertino JR, Göker E, Gorlick R, Li WW, Banerjee D. Resistance mechanisms to methotrexate in tumors. Stem Cells 1996; 14:5-9; PMID:8820944; http://dx.doi.org/10.1002/stem.140005
   PubMed Web of Science ®Google Scholar
• Olivotto M, Caldini R, Chevanne M, Cipolleschi MG. The respiration-linked step of tumor cell transition from the non-cycling to the cycling state: its inhibition by oxidizable substrates and its relationships to the purine metabolism. J Cell Physiol 1983; 116:149-58; PMID:6863398; http://dx.doi.org/10.1002/jcp.1041160205
   PubMed Web of Science ®Google Scholar
• Yoshida T. Experimental production of tumours by subcutaneous injection of an olive oil solution of o-aminoazotoluene. Gann 1932; 28:441-57
   Google Scholar
• Flintoff WF, Nagainis CR. Transport of methotrexate in Chinese hamster ovary cells: a mutant defective in methotrexate uptake and cell binding. Arch Biochem Biophys 1983; 223:433-40; PMID:6859869; http://dx.doi.org/10.1016/0003-9861(83)90607-0
   PubMed Web of Science ®Google Scholar
• Stivarou T, Cipolleschi MG, D'Amico M, Mannini A, Mini E, Rovida E, Dello Sbarba P, Olivotto M, Marzi I. The complex metabolic network gearing the G1/S transition in leukemic stem cells: Hints to a rational use of antineoplastic agents. Oncotarget 2015; 6:31985-96; PMID:26396171
   PubMed Web of Science ®Google Scholar
• Maden BE. Tetrahydrofolate and tetrahydromethanopterin compared: functionally distinct carriers in C1 metabolism. Biochem J 2000; 350:609-29; PMID:10970772; http://dx.doi.org/10.1042/bj3500609
   PubMed Web of Science ®Google Scholar
• Sur P, Doig MT, Priest DG. Response of methylentetrahydrofolate levels to methotrexate in Krebs ascites cells. Biochem J 1982; 216:295-8; http://dx.doi.org/10.1042/bj2160295
   Web of Science ®Google Scholar
• Gonen N, Assaraf YG. Antifolates in cancer therapy: Structure, activity and mechanism of drug resistance. Drug resistance update 2012; 15:183-210; http://dx.doi.org/10.1016/j.drup.2012.07.002
   PubMed Web of Science ®Google Scholar
• Hillcoat BL, Marshall L, Patterson J. Dihydrofolate reductase induced by folic acid in cultured human cells. Biochem Biophys Acta 1973; 293:281-4; PMID:4685281
   PubMed Web of Science ®Google Scholar
• Cipolleschi MG, Marzi I, Rovida E, Dello Sbarba P. Chronic myeloid leukemia and hepatoblastoma: Two cancer models to link metabolism to stem cells. Front Oncol 2016; 6:95
   PubMed Web of Science ®Google Scholar
• Olivotto M, Dello Sbarba P. Environmental restrictions within tumor ecosystem select for a convergent, hypoxia-resistant phenotype of cancer stem cells. Cell Cycle 2008; 13:3169-75
   Google Scholar
• Tedeschi PM, Markert EK, Gounder M, Lin H, Dvorzhinski D, Dolfi SC, Chan LL, Qiu J, DiPaola RS, Hirshfield KM, et al. Contribution of serine, folate and glycine metabolism to the ATP, NADPH and purine requirements of cancer cells. Cell Death Dis 2013; 4:e877; PMID:24157871; http://dx.doi.org/10.1038/cddis.2013.393
   PubMedGoogle Scholar
• Folmes CD, Nelson TJ, Martinez-Fernandez A, Arrel DK, Lindor JZ, Dzeja PP, Ikeda Y, Perez-Terzic C, Terzic A. Somatic oxidative bioenergetics transitions into pluripotency-dependent glycolysis to facilitate nuclear reprogramming. Cell Metab 2011; 14:264-71; PMID:21803296; http://dx.doi.org/10.1016/j.cmet.2011.06.011
   PubMed Web of Science ®Google Scholar
• Rovida E, Peppicelli S, Bono S, Bianchini F, Tusa I, Cheloni G, Marzi I, Cipolleschi MG, Calorini L, Dello Sbarba P. The metabolically-modulated stem cell niche: a dynamic scenario regulating cancer cell phenotype and resistance to therapy. Cell Cycle 2014; 7:176-8
   Google Scholar
• Robien K. Folate during antifolate chemotherapy: what we know... and do not know. Nutr Clin Pract 2005; 20:411-22; PMID:16207681; http://dx.doi.org/10.1177/0115426505020004411
   PubMedGoogle Scholar
• Alati T, Worzalla JF, Shih C, Bewley JR, Lewis S, Moran RG, Grindey GB. Augmentation of the therapeutic activity of lometrexol (6-R)5,10-dideazatetrahydrofolate by oral folic acid. Cancer Res 1996; 56:2331-5; PMID:8625328
   PubMed Web of Science ®Google Scholar
• Rycyna KJ, Bacich DJ, O'Keefe DS. Opposing roles of folate in prostate cancer. Urology 2013; 82:1197-2; PMID:23992971; http://dx.doi.org/10.1016/j.urology.2013.07.012
   PubMed Web of Science ®Google Scholar
• Holmes RS, Zheng Y, Baron JA, Li L, McKeown-Eyssen G, Newcomb PA, Stern MC, Haile RW, Grady WM, Potter JD, Le Marchand L, et al. Colon Cancer Family Registry. Use of folic acid-containing supplements after a diagnosis of colorectal cancer in the Colon Cancer Family Registry. Cancer Epidemiol Biomarkers Prev 2010; 19:2023-34; PMID:20696661; http://dx.doi.org/10.1158/1055-9965.EPI-09-1097
   PubMed Web of Science ®Google Scholar
• Blagosklonny MV. Carcinogenesis, cancer therapy and chemoprevention. Cell Death Differ 2005; 12:592-602; PMID:15818400; http://dx.doi.org/10.1038/sj.cdd.4401610
   PubMed Web of Science ®Google Scholar
• Blagosklonny MV. Antiangiogenic therapy and tumor progression. Cancer Cell 2004; 5:13-7. Erratum in: Cancer Cell. 2004; 6:425; http://dx.doi.org/10.1016/S1535-6108(03)00336-2
   PubMed Web of Science ®Google Scholar